We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-11.56%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$375M
AUM Growth
-$22.1M
Cap. Flow
+$63.9M
Cap. Flow %
17.03%
Top 10 Hldgs %
64.63%
Holding
62
New
5
Increased
7
Reduced
14
Closed
5

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$30.6M
2
NKTX icon
Nkarta
NKTX
+$10.9M
3
LYRA
LYRA THERAPEUTICS INC
LYRA
+$9.68M
4
HLVX
HilleVax
HLVX
+$9.06M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$8.95M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$3.17M
2
RXRX icon
Recursion Pharmaceuticals
RXRX
+$1.81M
3
TIL icon
Instil Bio
TIL
+$1.44M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$1.37M
5
SWTX
SpringWorks Therapeutics
SWTX
+$1.35M

Sector Composition

Rank Sector Weight
1 Healthcare 97.54%
2 Financials 2.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBTX
26
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$3.38M 0.9%
801,629
-24,793
-3% -$58.6K
BLSA
27
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$2.97M 0.79%
300,000
– –
TNGX icon
28
Tango Therapeutics
TNGX
$4.72B
$2.85M 0.76%
630,000
– –
IGMS
29
DELISTED
IGM Biosciences
IGMS
$2.79M 0.74%
154,664
– –
VIRX
30
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.68M 0.71%
689,709
-21,330
-3% -$60.8K
RXRX icon
31
Recursion Pharmaceuticals
RXRX
$1.7B
$2.18M 0.58%
267,996
-271,240
-50% -$1.81M
BOLT icon
32
Bolt Biotherapeutics
BOLT
$7.44M
$2.14M 0.57%
52,458
– –
AMYT
33
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$2.13M 0.57%
304,715
+25,000
+9% +$195K
ALXO icon
34
ALX Oncology
ALXO
$284M
$2.13M 0.57%
262,786
– –
ALBO
35
DELISTED
Albireo Pharma Inc
ALBO
$1.99M 0.53%
100,000
– –
SYRS
36
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.83M 0.49%
189,962
– –
SNCE
37
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$1.81M 0.48%
45,000
– –
AVDL
38
DELISTED
Avadel Pharmaceuticals
AVDL
$1.61M 0.43%
659,409
– –
RYTM icon
39
Rhythm Pharmaceuticals
RYTM
$7.72B
$1.43M 0.38%
345,293
– –
EQ icon
40
Equillium
EQ
$134M
$1.26M 0.33%
615,541
– –
VTVT icon
41
vTv Therapeutics
VTVT
$136M
$1.23M 0.33%
40,888
– –
NVAX icon
42
CALL
Novavax
NVAX
$1.27B
$1.2M 0.32%
23,400
– –
ELEV
43
DELISTED
Elevation Oncology
ELEV
$1.16M 0.31%
830,565
-101,675
-11% -$255K
NVAX icon
44
Novavax
NVAX
$1.27B
$1.09M 0.29%
21,244
-5,900
-22% -$306K
SRZN icon
45
Surrozen
SRZN
$251M
$900K 0.24%
20,000
– –
TERN
46
DELISTED
Terns Pharmaceuticals
TERN
$717K 0.19%
289,068
– –
BCEL
47
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$710K 0.19%
396,835
– –
SWTX
48
DELISTED
SpringWorks Therapeutics
SWTX
$547K 0.15%
22,204
-37,000
-62% -$1.35M
ALLK
49
DELISTED
Allakos
ALLK
$539K 0.14%
172,089
– –
SYRE icon
50
Spyre Therapeutics
SYRE
$9.12B
$446K 0.12%
35,349
– –
1
2
3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return

Samsara BioCapital's Q2 2022 Portfolio in Review

As of Q2 2022, Samsara BioCapital held 62 positions worth $375M, down 5.6% from $397M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Samsara BioCapital deployed $63.9M of net new capital in Q2 2022, opening 5 new positions and adding to 7 existing holdings. Its largest new stake was LYRA THERAPEUTICS INC: 35,545 shares worth $10M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $3.17M trimmed.

  • Samsara BioCapital's largest Q2 2022 buy was LYRA THERAPEUTICS INC: 35,545 shares worth $10M.
  • Samsara BioCapital added most to Scholar Rock in Q2 2022, an estimated $30.6M increase.
  • Samsara BioCapital's biggest Q2 2022 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $3.17M.
  • Samsara BioCapital fully exited Odonate Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $925K.
  • Samsara BioCapital's ten largest holdings make up 65% of its $375M portfolio in Q2 2022.
  • Samsara BioCapital opened 5 new positions and closed 5 in Q2 2022.
  • Samsara BioCapital's portfolio value fell 5.6% quarter-over-quarter to $375M.

Based on Samsara BioCapital's 13F filing for Q2 2022, filed 15 Aug 2022.